论文部分内容阅读
目的:观察红景天苷预处理对兔肢体缺血再灌注后心脏的保护作用。方法:24只新西兰兔随机均分为:假手术组、缺血再灌注安慰剂组(缺血再灌注组)、红景天苷预处理组(红景天苷组)。建模前预处理组在耳缘静脉注射红景天苷注射液,缺血再灌注组注射生理盐水,每天1次,连续3 d。建模后,心脏超声评估再灌注4h时的各组兔心功能,包括左室收缩末期内径(LVESd)、左室舒张末期内径(LVEDd)、左室射血分数(LVEF)、左室短轴缩短率(FS),同时采血检测血清心肌肌钙蛋白I(cTnI)、肿瘤坏死因子(TNF)-α,然后取心室组织进行病理切片观察,另取部分心室组织匀浆检测超氧化物歧化酶(SOD)、丙二醛(MDA)。结果:再灌注4h时,与缺血再灌注组比较,红景天苷组LVESd[(0.69±0.07)mm比(0.62±0.05)mm]显著减少,LVEF[(64.6±3.4)%比(72.1±3.6)%]、FS[(34.2±3.2)%比(41.7±3.4)%]显著增加(P均<0.05),但红景天苷组这些指标与假手术组比较无显著差异。与缺血再灌注组比较,红景天苷组cTnI[(5.24±0.34)μg/L比(1.06±0.12)μg/L]、MDA[(8.92±2.18)μmol/L比(6.79±1.43)μmol/L]、TNF-α[(37.43±10.02)pg/L]比(19.73±6.31)pg/L]]水平明显下降,SOD[(16.61±3.75)U/ml比(22.26±4.73)U/ml]水平明显上升(P均<0.05)。病理结果显示预处理组损伤程度明显轻于缺血再灌注组。结论:红景天苷预处理可以减轻兔肢体缺血再灌注后心脏损伤,保护心功能。
OBJECTIVE: To observe the protective effect of salidroside on rabbit hearts after ischemia and reperfusion. METHODS: Twenty-four New Zealand rabbits were randomly divided into sham operation group, placebo group (ischemic reperfusion group), and salidroside pretreatment group (rhizide group). Before the modeling, the pretreatment group received salidroside injection in the ear vein, and the ischemia-reperfusion group received normal saline once a day for 3 days. After modeling, cardiac ultrasound assessed cardiac function in all groups at 4 h after reperfusion, including left ventricular end-systolic diameter (LVESd), left ventricular end-diastolic dimension (LVEDd), left ventricular ejection fraction (LVEF), and left ventricular short axis The rate of shortening (FS) was measured by measuring the serum levels of cardiac troponin I (cTnI) and tumor necrosis factor (TNF)-α at the same time. The ventricular tissues were then taken for pathological section observation, and some of the ventricular homogenates were also used to detect superoxide dismutase (SOD). (SOD), malondialdehyde (MDA). RESULTS: Compared with the ischemia-reperfusion group, the LVESd ratio in the salidroside group was significantly lower than that in the ischemia-reperfusion group (0.69±0.07 mm vs. 0.62±0.05 mm), and the ratio of LVEF was (64.6±3.4)%. There was a significant increase in ± 3.6)%] and FS [(34.2 ± 3.2)% vs. (41.7 ± 3.4)%] (P < 0.05), but there was no significant difference between the salidroside group and the sham group. Compared with the ischemia-reperfusion group, the cTnI of the salidroside group was [(5.24±0.34) μg/L vs. (1.06±0.12) μg/L] and that of the MDA [(8.92±2.18) μmol/L] (6.79±1.43). The level of μmol/L] and TNF-α [(37.43±10.02) pg/L] was significantly lower than that of (19.73±6.31) pg/L]], and the SOD was (16.61±3.75)U/ml ratio (22.26±4.73)U. /ml] levels increased significantly (P all < 0.05). Pathological results showed that the extent of injury in the pretreatment group was significantly lighter than that in the ischemia-reperfusion group. CONCLUSION: Pretreatment with salidroside can reduce cardiac injury and protect heart function after limb ischemia-reperfusion in rabbits.